JP2012509348A5 - - Google Patents

Download PDF

Info

Publication number
JP2012509348A5
JP2012509348A5 JP2011537624A JP2011537624A JP2012509348A5 JP 2012509348 A5 JP2012509348 A5 JP 2012509348A5 JP 2011537624 A JP2011537624 A JP 2011537624A JP 2011537624 A JP2011537624 A JP 2011537624A JP 2012509348 A5 JP2012509348 A5 JP 2012509348A5
Authority
JP
Japan
Prior art keywords
disease
pharmaceutically acceptable
acceptable salt
composition
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011537624A
Other languages
English (en)
Other versions
JP2012509348A (ja
JP5535233B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/065188 external-priority patent/WO2010059853A1/en
Publication of JP2012509348A publication Critical patent/JP2012509348A/ja
Publication of JP2012509348A5 publication Critical patent/JP2012509348A5/ja
Application granted granted Critical
Publication of JP5535233B2 publication Critical patent/JP5535233B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (10)

  1. 化学構造：
    Figure 2012509348
     を有する化合物Ｉｈ３ｅ、または薬学的に許容されるその塩、水和物、あるいはそのグリシンアミノ酸抱合体またはタウリンアミノ酸抱合体。
  2. グリシンアミノ酸抱合体である、請求項１に記載の化合物。
  3. タウリンアミノ酸抱合体である、請求項１に記載の化合物。
  4. 薬学的に許容される塩である、請求項１から３のいずれか一項に記載の化合物。
  5. 請求項１から４のいずれか一項に記載の化合物、または薬学的に許容されるその塩、もしくは水和物と、少なくとも１種の薬学的に許容される賦形剤とを含む、薬学的に許容される組成物。
  6. 被験体において疾患を治療または予防するための組成物であって、該組成物は、請求項１から４のいずれか一項に記載の化合物、または薬学的に許容されるその塩もしくは水和物を含み、さらに該疾患は、代謝性疾患、炎症性疾患、肝疾患、自己免疫疾患、心臓疾患、腎臓疾患、癌、および胃腸疾患から選択される、組成物。
  7. 前記疾患は、糖尿病である、請求項６に記載の組成物。
  8. 前記疾患は、肥満症である、請求項６に記載の組成物。
  9. 前記疾患は、糖尿肥満である、請求項６に記載の組成物。
  10. 請求項１から４のいずれか一項に記載の化合物、または薬学的に許容されるその塩、もしくは水和物を含む、被験体において疾患を治療または予防するためのキット。
JP2011537624A 2008-11-19 2009-11-19 Ｔｇｒ５モジュレーターおよびその使用方法 Expired - Fee Related JP5535233B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08169462 2008-11-19
EP08169462.2 2008-11-19
PCT/US2009/065188 WO2010059853A1 (en) 2008-11-19 2009-11-19 Tgr5 modulators and method of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014088019A Division JP2014159456A (ja) 2008-11-19 2014-04-22 Ｔｇｒ５モジュレーターおよびその使用方法

Publications (3)

Publication Number Publication Date
JP2012509348A JP2012509348A (ja) 2012-04-19
JP2012509348A5 true JP2012509348A5 (ja) 2012-12-13
JP5535233B2 JP5535233B2 (ja) 2014-07-02

Family

ID=41668454

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2011537624A Expired - Fee Related JP5535233B2 (ja) 2008-11-19 2009-11-19 Ｔｇｒ５モジュレーターおよびその使用方法
JP2014088019A Withdrawn JP2014159456A (ja) 2008-11-19 2014-04-22 Ｔｇｒ５モジュレーターおよびその使用方法
JP2015160141A Pending JP2015232020A (ja) 2008-11-19 2015-08-14 Ｔｇｒ５モジュレーターおよびその使用方法
JP2017083045A Withdrawn JP2017132803A (ja) 2008-11-19 2017-04-19 Ｔｇｒ５モジュレーターおよびその使用方法
JP2018059922A Withdrawn JP2018100304A (ja) 2008-11-19 2018-03-27 Ｔｇｒ５モジュレーターおよびその使用方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2014088019A Withdrawn JP2014159456A (ja) 2008-11-19 2014-04-22 Ｔｇｒ５モジュレーターおよびその使用方法
JP2015160141A Pending JP2015232020A (ja) 2008-11-19 2015-08-14 Ｔｇｒ５モジュレーターおよびその使用方法
JP2017083045A Withdrawn JP2017132803A (ja) 2008-11-19 2017-04-19 Ｔｇｒ５モジュレーターおよびその使用方法
JP2018059922A Withdrawn JP2018100304A (ja) 2008-11-19 2018-03-27 Ｔｇｒ５モジュレーターおよびその使用方法

Country Status (23)

Country Link
US (5) US8114862B2 (ja)
EP (2) EP2698375B1 (ja)
JP (5) JP5535233B2 (ja)
KR (2) KR101789960B1 (ja)
CN (2) CN102325784B (ja)
AU (1) AU2009316566B9 (ja)
BR (1) BRPI0921983B8 (ja)
CA (1) CA2744189C (ja)
DK (2) DK2698375T3 (ja)
EA (2) EA020140B1 (ja)
ES (2) ES2458168T3 (ja)
HK (2) HK1166327A1 (ja)
HU (1) HUE039171T2 (ja)
IL (3) IL212969A (ja)
LT (1) LT2698375T (ja)
MX (1) MX2011005295A (ja)
NO (1) NO2698375T3 (ja)
PL (2) PL2698375T3 (ja)
PT (2) PT2698375T (ja)
SG (1) SG10201400162QA (ja)
SI (1) SI2698375T1 (ja)
WO (1) WO2010059853A1 (ja)
ZA (1) ZA201104077B (ja)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4021327B2 (ja) 2001-03-12 2007-12-12 インターセプト ファーマスーティカル インコーポレイテッド Ｆｘｒに対する作用薬としてのステロイド
US10987362B2 (en) 2004-03-12 2021-04-27 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using FXR ligands
DK2712617T3 (en) 2004-03-12 2017-02-13 Intercept Pharmaceuticals Inc Treatment of fibrosis with Fxr ligands.
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
MX2009007728A (es) 2007-01-19 2009-12-15 Intercept Pharmaceuticals Inc Acidos biliares 23-sustituidos como moduladores de tgr5 y metodos de uso de los mismos.
WO2010014836A2 (en) 2008-07-30 2010-02-04 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
KR101789960B1 (ko) * 2008-11-19 2017-10-25 인터셉트 파마슈티컬즈, 인크. Tgr5 조절제 및 그의 사용 방법
JP2012509892A (ja) 2008-11-26 2012-04-26 サティオゲン ファーマシューティカルズ，インク． サティオゲン類を含有する組成物及び使用の方法
WO2010062861A2 (en) 2008-11-26 2010-06-03 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
EP2995317A1 (en) 2010-05-26 2016-03-16 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
MX354242B (es) 2011-10-28 2018-02-20 Lumena Pharmaceuticals Inc Nhibidores de la recirculación de ácidos biliares para el tratamiento de enfermedades hepáticas colestásicas pediátricas.
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
CN104781272A (zh) 2012-06-19 2015-07-15 英特塞普特医药品公司 奥贝胆酸的制备、用途和固体形式
US10302630B2 (en) 2012-10-09 2019-05-28 The Procter & Gamble Company Method of identifying or evaluating beneficial actives and compositions containing the same
WO2014059009A1 (en) 2012-10-09 2014-04-17 The Procter & Gamble Company Method of identifying synergistic cosmetic combinations
CN105408343B (zh) * 2013-06-06 2018-08-03 耶路撒冷希伯来大学伊森姆研究发展有限公司 胆汁酸-碱性氨基酸缀合物及其用途
CN105636984A (zh) * 2013-06-13 2016-06-01 法斯特弗沃德制药有限公司 用于治疗慢性炎症和预防胃肠道癌或纤维化的cd40信号转导抑制剂和其他化合物，该其他化合物是胆汁酸、胆汁酸衍生物、tgr5受体激动剂、fxr激动剂或其组合
KR102507624B1 (ko) 2013-11-22 2023-03-09 미나 테라퓨틱스 리미티드 Ｃ/ｅｂｐ 알파 짧은 활성화 ｒｎａ 조성물 및 사용 방법
PL3626725T3 (pl) * 2014-05-29 2023-04-03 Bar Pharmaceuticals S.R.L. Pochodne cholanu do zastosowania w leczeniu i/lub zapobieganiu chorobom, w których pośredniczy fxr i tgr5/gpbar1
WO2016054208A1 (en) * 2014-10-03 2016-04-07 Mayo Foundation For Medical Education And Research Targeting tgr5 to treat disease
RU2017118569A (ru) * 2014-11-06 2018-12-06 Энанта Фармасьютикалс, Инк. Аналоги желчных кислот как агонисты fxr/tgr5 и способы их применения
EP3221332B1 (en) 2014-11-19 2019-04-24 NZP UK Limited 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators
CA2968309A1 (en) 2014-11-19 2016-05-26 NZP UK Limited 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators
US20170327531A1 (en) 2014-11-19 2017-11-16 NZP UK Limited 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators
MX2017006565A (es) 2014-11-19 2018-01-26 Nzp Uk Ltd Esteroides 6.alfa.-alquil-3,7-diona como intermedios para la produccion de moduladores esteroides del receptor x farnesoide (fxr).
CN105985396A (zh) * 2015-02-16 2016-10-05 苏州泽璟生物制药有限公司 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
CN107250150B (zh) * 2015-04-28 2019-11-22 江苏豪森药业集团有限公司 胆酸衍生物及其制备方法和医药用途
DK3310801T3 (da) 2015-06-19 2021-06-21 Intercept Pharmaceuticals Inc Tgr5-modulatorer og fremgangsmåder til anvendelse deraf
CA2989167A1 (en) * 2015-06-19 2016-12-22 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
US11072631B2 (en) * 2015-09-24 2021-07-27 Intercept Pharmaceuticals, Inc. Methods and intermediates for the preparation bile acid derivatives
US11034717B2 (en) * 2015-10-07 2021-06-15 Intercept Pharmaceuticals, Inc. Farnesoid X receptor modulators
CN109467585A (zh) * 2016-03-11 2019-03-15 深圳市塔吉瑞生物医药有限公司 用于预防或治疗fxr-介导疾病的胆烷酸化合物
JP6968821B2 (ja) 2016-04-13 2021-11-17 インターセプト ファーマシューティカルズ， インコーポレイテッド 癌を治療する方法
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
US10654834B2 (en) * 2016-07-01 2020-05-19 Venenum Biodesign, LLC Non-systemic TGR5 agonists
WO2018222701A1 (en) * 2017-05-30 2018-12-06 Intercept Pharmaceuticals, Inc. Treatment of renal diseases with a bile acid derivative
CN109021056B (zh) * 2017-06-09 2021-03-09 博瑞生物医药（苏州）股份有限公司 法尼酯x受体激动剂
CN111050772A (zh) 2017-07-24 2020-04-21 英特塞普特医药品公司 同位素标记的胆汁酸衍生物
CA3075205A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited Stabilized hnf4a sarna compositions and methods of use
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
WO2020163201A1 (en) * 2019-02-04 2020-08-13 Intercept Pharmaceuticals, Inc. Treatment and prevention of intestinal inflammatory diseases with a bile acid derivative
CN116925168A (zh) * 2019-08-23 2023-10-24 深圳云合医药科技合伙企业(有限合伙) 胆汁酸衍生物及其组合物和应用
BR112022006546A2 (pt) 2019-10-07 2022-08-30 Kallyope Inc Agonistas de gpr119
BR112022023359A2 (pt) 2020-05-19 2023-04-18 Kallyope Inc Ativadores de ampk
EP4172162A1 (en) 2020-06-26 2023-05-03 Kallyope, Inc. Ampk activators
KR20220004451A (ko) * 2020-07-03 2022-01-11 연세대학교 산학협력단 지방간 질환의 예방 또는 치료를 위한 약학적 조성물
CN113774142A (zh) * 2021-10-11 2021-12-10 北京化工大学 Tgr5在制备治疗肠癌药物及诊断性试剂盒中的应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0101554B1 (en) 1982-07-29 1986-10-15 Lehner A.G. New derivatives of biliary acids, process for the production thereof and pharmaceutical compositions containing the same
IT1206112B (it) 1983-04-29 1989-04-14 Lehner Ag Nuovi derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche.
IT1212835B (it) 1983-08-18 1989-11-30 Lehner Ag Derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche.
US4892868A (en) * 1984-08-17 1990-01-09 Gipharmex, S.P.A. Derivatives of biliary acids, process for the production thereof and corresponding pharmaceutical compositions
IT1196377B (it) 1984-12-21 1988-11-16 Lehner Ag Derivati di acidi biliari,procedimento per la loro preparazione e relative composizioni farmaceutiche
IT1223313B (it) 1987-10-20 1990-09-19 Gipharmex Spa Derivati di acidi biliari loro preparazione e composizioni farmaceutiche che li contengono
IT1229570B (it) * 1989-04-17 1991-09-04 Giuliani Spa Derivati fluorurati di acidi biliari, loro preparazione e composizioni farmaceutiche che li contengono.
US5175320A (en) * 1989-04-17 1992-12-29 Giuliani S.P.A. Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
DE69018592T2 (de) * 1989-12-13 1995-10-05 Mitsubishi Chem Corp Pyrazolylacrylsäure-Derivate, verwendbar als systemische Fungiziden in Pflanzen- und Materialschutz.
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
US5689791A (en) 1996-07-01 1997-11-18 Xerox Corporation Electrically conductive fibers
BR9710272A (pt) 1996-07-12 1999-08-10 Smithkline Beecham Plc Novo tratamento de resisténcia a leptina
US6008237A (en) * 1997-12-19 1999-12-28 Merck & Co., Inc. Arylthiazolidinedione derivatives
WO1999038845A1 (en) 1998-01-29 1999-08-05 Tularik Inc. Ppar-gamma modulators
EP1137940A4 (en) 1998-10-23 2004-06-02 Glaxo Group Ltd METHOD FOR IDENTIFYING LIGANDS OF NUCLEAR RECEPTORS
EP1140079B1 (en) * 1998-12-23 2009-06-03 Glaxo Group Limited Assays for ligands for nuclear receptors
AU2409600A (en) 1999-01-07 2000-07-24 Tularik Inc. Fxr receptor-mediated modulation of cholesterol metabolism
EP1473042B1 (en) 1999-03-26 2006-06-21 City of Hope Screening for FXR receptor modulators
DE60013417T2 (de) 1999-03-26 2005-09-15 City Of Hope, Duarte Verfahren zum screenen von fxr-rezeptormodulatoren
US20020132223A1 (en) 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
CA2377320A1 (en) 1999-06-11 2000-12-21 Allergan Sales, Inc. Methods for modulating fxr receptor activity
US6906057B1 (en) * 1999-06-11 2005-06-14 Allergan, Inc. Methods for modulating FXR receptor activity
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
AU1215701A (en) 1999-10-22 2001-05-08 Merck & Co., Inc. Pharmaceuticals for treating obesity
CA2401290A1 (en) 2000-04-12 2001-10-18 Takeda Chemical Industries, Ltd. Novel g protein-coupled receptor protein and dna thereof
US6627636B2 (en) * 2000-06-15 2003-09-30 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
WO2002020463A2 (en) 2000-09-05 2002-03-14 Tularik Inc. Fxr modulators
US20020119958A1 (en) 2001-02-13 2002-08-29 Shinichiro Tojo Therapeutic agent for hyperlipidemia
JP4021327B2 (ja) 2001-03-12 2007-12-12 インターセプト ファーマスーティカル インコーポレイテッド Ｆｘｒに対する作用薬としてのステロイド
US7354726B2 (en) 2001-04-12 2008-04-08 Takeda Pharmaceutical Company Limited Screening method
WO2003016280A1 (en) 2001-08-13 2003-02-27 Lion Bioscience Ag Nr1h4 nuclear receptor binding compounds
ATE381542T1 (de) 2001-08-13 2008-01-15 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
EP1423113A4 (en) 2001-08-13 2007-04-18 Phenex Pharmaceuticals Ag NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS
US20030144360A1 (en) 2001-11-19 2003-07-31 Allergan Sales, Inc. Composition and method for modulating BAR/FXR receptor activity
WO2003080803A2 (en) 2002-03-21 2003-10-02 Smithkline Beecham Corporation Methods of using farnesoid x receptor (fxr) agonists
AU2003228485A1 (en) 2002-04-12 2003-10-27 The University Of Chicago Farnesoid x-activated receptor agonists
US6987121B2 (en) 2002-04-25 2006-01-17 Smithkline Beecham Corporation Compositions and methods for hepatoprotection and treatment of cholestasis
MXPA05000008A (es) 2002-06-19 2005-04-08 Availvs Corp Material de muro de piedra artificial.
ITMI20021532A1 (it) 2002-07-12 2004-01-12 Roberto Pellicciari Composti chimici
WO2004048349A1 (en) 2002-11-22 2004-06-10 Smithkline Beecham Corporation Farnesoid x receptor agonists
WO2004067008A1 (ja) 2003-01-28 2004-08-12 Takeda Pharmaceutical Company Limited 受容体作動薬
WO2005032549A1 (en) 2003-09-26 2005-04-14 Smithkline Beecham Corporation Compositions and methods for treatment of fibrosis
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
DK2712617T3 (en) 2004-03-12 2017-02-13 Intercept Pharmaceuticals Inc Treatment of fibrosis with Fxr ligands.
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
SI2040713T1 (sl) 2006-06-27 2014-11-28 Intercept Pharmaceuticals, Inc. Derivati žolčne kisline kot FXR ligandi za preprečevanje ali zdravljenje bolezni ali stanj, posredovanih s FXR
MX2009007728A (es) * 2007-01-19 2009-12-15 Intercept Pharmaceuticals Inc Acidos biliares 23-sustituidos como moduladores de tgr5 y metodos de uso de los mismos.
EP1947108A1 (en) 2007-01-19 2008-07-23 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
KR101789960B1 (ko) * 2008-11-19 2017-10-25 인터셉트 파마슈티컬즈, 인크. Tgr5 조절제 및 그의 사용 방법

Similar Documents

Publication Publication Date Title
JP2012509348A5 (ja)
JP2018518537A5 (ja)
EP2698375A3 (en) TGR5 modulators and method of use thereof
JP2009502793A5 (ja)
JP2009545527A5 (ja)
JP2013507439A5 (ja)
JP2012512907A5 (ja)
JP2010521516A5 (ja)
JP2009501202A5 (ja)
JP2008517059A5 (ja)
JP2014012726A5 (ja)
JP2006515626A5 (ja)
JP2008536853A5 (ja)
JP2012509349A5 (ja)
JP2007526248A5 (ja)
JP2010515715A5 (ja)
JP2008533007A5 (ja)
JP2015145410A5 (ja)
EA200971130A1 (ru) Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
JP2011520965A5 (ja)
JP2010530897A5 (ja)
JP2010521514A5 (ja)
JP2006526031A5 (ja)
JP2014526441A5 (ja)
JP2012504619A5 (ja)